



Millions worldwide could benefit after a breakthrough trial in the treatment for Alzheimer's by Aussie biotech Actinogen

Aussie biotech firm Actinogen has announced that their most recent trial of Xanamem has demonstrated improved attention and working memory.

Sydney, 27 April 2022. Actinogen Medical has announced positive results for their lead drug Xanamem taking the Aussie biotech a big step closer to creating a novel treatment for a disease that impacts over 400,000 elderly Australians.

“These results are an important replication of previous trial findings also conducted in a cognitively normal population. The positive effects on attention and working memory seen in the XanaMIA trial are a significant step in the development of a new treatment for Alzheimer’s Disease with a novel mechanism of action,” said international cognition expert, Professor John Harrison.

In a release to the ASX Actinogen reported that the trial had met its objectives with the efficacy endpoint of the Xanamem trial defined as clinically significant on the treatment on cognitive ability and confirmed Xanamem’s ability to enhance attention and working memory whilst demonstrating a good safety profile.

“We are excited to see the positive clinical data for these lower Xanamem dose levels. Xanamem has the potential to be a novel daily oral therapy for Alzheimer’s Disease and other conditions that could be safely used alone or in combination with other therapies. Our future clinical trials will evaluate if Xanamem can make a significant improvement in the lives of patients and their families living with serious neurological conditions,” said Actinogen’s CEO Dr Steven Gourlay.

The Xanamem low dose-ranging trial was conducted in a population of 107 healthy, cognitively normal, older adults aged 50-80 years, with a mean age of 64 years and a gender ratio of one male to two females, with trial participants randomised to receive either 10 mg or 5 mg doses of Xanamem or matching placebo for a six-week treatment period.

It is the second trial conducted by Actinogen that has shown positive results for the potential treatment of Alzheimer’s by Actinogen’s lead drug Xanamem moving the Aussie biotech a big step closer to a groundbreaking treatment of a condition that impacts millions worldwide.

Actinogen will now review detailed results of the Xanamem trial with academic and industry experts as it finalises the design of its next Alzheimer’s disease program trial. Detailed results will be published at a future scientific congress and in a peer reviewed journal.

WEBCAST

All media are invited to a webcast from Actinogen CEO Dr Steven Gourlay and CMO Professor Paul Rolan at 11am AEST April 27 to review the topline results of the Xanamem. The webcast and teleconference call can be accessed via the Actinogen website: www.actinogen.com.au

END OF RELEASE

Media Contact

Randal Killip

Profile for Media

M: +61 425 714 159

E. randal@profileformedia.com.au

About Actinogen Medical

Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological diseases associated with dysregulated brain cortisol. There is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long-term cognitive health.

Cognitive function means how a person understands, remembers and thinks clearly. Cognitive functions include memory, attention, reasoning, awareness and decision-making.

We are currently developing our lead compound, Xanamem®, as a promising new therapy for Alzheimer's Disease, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. The cognitive dysfunction, behavioural abnormalities, and neuropsychological burden associated with these conditions is debilitating for patients, and there is a substantial unmet medical need for new and improved treatments.

About Xanamem

Xanamem's novel mechanism of action works by blocking the production of intracellular cortisol through the inhibition of the 11 β -HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule.

Chronically elevated cortisol is associated with cognitive decline in [Alzheimer's Disease](#), potentially linked to cognitive impairment and anxiety in [Fragile X Syndrome](#), and cognitive impairment in Depression and other diseases.

The Company has studied 11 β -HSD1 inhibition by Xanamem in more than 300 volunteers and patients, so far finding a statistically significant improvement in cognition over placebo in healthy, older volunteers. A series of Phase 2 studies in multiple diseases is being conducted to further confirm and characterise Xanamem's therapeutic potential.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem® is a trademark of Actinogen Medical.